companydata.dkNovo Nordisk Invest 4 A/S: Financial statements 2020
CVR: 31853923
Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2020. In 2020, the company reported a net result of DKK -108,000 compared with DKK -398,000 the year before. Equity amounted to DKK 1,816,000. The solvency ratio was 79.8%.
- Profit/Loss
- -108,000 kr.
- Equity
- 1,816,000 kr.
- Total Assets
- 2,276,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | - | -108 t. | 1.8 mio. | - |
| 2019 | - | - | -398 t. | 8.9 mio. | - |
| 2018 | - | - | 189 t. | 9.3 mio. | - |
| 2017 | - | - | -775 t. | 9.1 mio. | - |
| 2016 | - | - | -407 t. | 9.9 mio. | - |
How creditworthy is Novo Nordisk Invest 4 A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of December 15, 2020, Linette Tangsgaard Nielsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of December 15, 2020, Lene Moth Bang has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2019. The net result was DKK -398,000.
About Novo Nordisk Invest 4 A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.